Zacks Investment Research Upgrades Xoma (XOMA) to “Buy”
Xoma (NASDAQ:XOMA) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage currently has a $27.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 7.31% from the stock’s previous close.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
A number of other research firms also recently weighed in on XOMA. HC Wainwright set a $49.00 price target on shares of Xoma and gave the stock a “buy” rating in a research report on Monday, April 30th. ValuEngine raised shares of Xoma from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. TheStreet downgraded shares of Xoma from a “c-” rating to a “d” rating in a research report on Friday, April 6th. Finally, Cowen reissued a “hold” rating on shares of Xoma in a research report on Thursday, May 10th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $36.33.
Xoma (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.06. Xoma had a net margin of 40.44% and a negative return on equity of 670.15%. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $3.69 million. analysts anticipate that Xoma will post -0.86 EPS for the current fiscal year.
In other news, SVP Thomas M. Burns sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, April 27th. The shares were sold at an average price of $24.71, for a total transaction of $271,810.00. Following the completion of the sale, the senior vice president now owns 14,900 shares of the company’s stock, valued at $368,179. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James R. Neal sold 24,000 shares of the firm’s stock in a transaction that occurred on Friday, April 27th. The stock was sold at an average price of $24.51, for a total transaction of $588,240.00. Following the sale, the chief executive officer now directly owns 24,678 shares of the company’s stock, valued at approximately $604,857.78. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in shares of Xoma during the fourth quarter worth approximately $138,000. Acadian Asset Management LLC bought a new position in Xoma during the fourth quarter worth $152,000. GSA Capital Partners LLP bought a new position in Xoma during the first quarter worth $243,000. Allianz Asset Management GmbH lifted its stake in Xoma by 32.7% during the first quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 3,020 shares during the last quarter. Finally, Gotham Asset Management LLC bought a new position in Xoma during the fourth quarter worth $267,000. 39.63% of the stock is owned by institutional investors and hedge funds.
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xoma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma and related companies with MarketBeat.com's FREE daily email newsletter.